Retrospective study for Lenvatinib for unresectable thyroid cancers

Retrospective study for Lenvatinib for unresectable thyroid cancers - Lenvatinib for thyroid cancers

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030969

Enrollment

Registered

2018-01-24

Start date

2018-01-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable thyroid cacers

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Unresectable thyroid cacers treated by Lenvatinib

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Overall survival time	—

Secondary

Measure	Time frame
Adverse effects	—

Countries

Japan

Contacts

Public ContactAkihito Arai

Kyoto prefectural university of medicine Department of Otolaryngology Head and Neck Surgery

hirano@koto.kpu-m.ac.jp0752515603

Outcome results